Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01381432

Enrollment

Registered

2011-06-27

Start date

2004-12-31

Completion date

2011-05-31

Last updated

2013-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases

Keywords

Antirejection

Brief summary

This post-marketing surveillance study is to investigate the efficacy and safety of azathioprine tablets in subjects whom lung transplantation is performed.

Interventions

DRUGAzathioprine

At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Subjects who undergo lung transplantation and azathioprine tablets were administered

Exclusion criteria

* Subjects with hypersensitivity to the ingredients of azathioprine tablet * Subjects who is pregnant or might be pregnant * Subjects whose white count is lower than 3000/cubic millimeter

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events related to azathioprine tablets	3 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026